|
pmiCME Updates Track 1 |
|
To date, the following organizations have provided educational grants in support of pmiCME Updates
Track 1: Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through a collaboration with Eli Lilly and Company, Forest Research Institute, a subsidiary of Forest Laboratories, Inc., Purdue Pharma L.P., sanofi-aventis U.S. and Shire.
|
| 7:00 AM-7:50 AM |
Registration & Breakfast
|
| 7:50 AM-8:00 AM |
Opening Remarks
|
| 8:00 AM-9:30 AM |
Evidence Based Strategies to Improve Glycemic Control in Type 2 Diabetes
Learning Objectives:
- Apply current data from clinical trials for A1C goal setting and individualization of treatment
- Recognize the importance of timely initiation of drug therapy including the early insulin initiation in reducing the complications of type 2 diabetes
- Describe interdisciplinary team and collaborative care approaches that can improve clinical outcomes
- Identify and implement strategies for overcoming the barriers to insulin initiation and medication adherence.
Robert Tanenberg, MD, FACP , Professor of Medicine, Division of Endocrinology,
Brody School of Medicine,
East Carolina University ,
Greenville, NC
Michelle Magee, MD, MBBCh, BAO , Associate Professor of Medicine,
Director, MedStar Diabetes Institute (MDI),
Georgetown University School of Medicine,
Washington, DC, , Associate Professor of Medicine,
Director, MedStar Diabetes Institute (MDI),
Georgetown University School of Medicine,
Washington, DC
|
| 9:30 AM-9:45 AM |
AM Break
|
| 9:45 AM-11:00 AM |
Enhancing Patient Diagnosis and Management of COPD: A Case Based Review
Learning Objectives:
- Prevent COPD exacerbations by recognizing the clinical factors that put patients at risk and by improving early recognition and intervention
- Stratify COPD severity and develop individualized treatment plans on the basis of spirometry results
- Tailor therapies for COPD according to the standards set by evidence-based GOLD guidelines
Fernando J. Martinez, MD, MS , Professor,
Department of Internal Medicine,
Director,
Pulmonary Diagnostic Services,
University of Michigan,
Ann Arbor, MI
Stephen L Rennard, MD , Larson Professor,
Division of Pulmonary, Critical Care, Sleep and Allergy,
University of Nebraska Medical Center,
Omaha, NE
|
| 11:00 AM-12:15 PM |
Improving Opioid Safety: A Focus on Patient Education
Learning Objectives:
- Differentiate between opioid tolerance, dependence and addiction
- Incorporate screening tools that evaluate the risk of aberrant behavior and misuse of opioids
- Integrate patient education strategies to improve safety and reduce the risk of misuse and diversion
Steven D Passik, PhD , Professor of Psychiatry,
Professor of Anesthesiology,
Vanderbilt University School of Medicine,
Nashville, TN
Lynn R Webster, MD , FACPM , FASAM , Medical Director and Founder,
Lifetree Clinical Research & Pain Clinic,
Salt Lake City, UT
|
| 12:15 PM-1:00 PM |
Lunch
|
| 12:15 PM-1:00 PM |
Networking Break
|
| 1:00 PM-2:30 PM |
Managing Cardiometabolic Disease in Patients With, or at Risk for, Type 2 Diabetes
Learning Objectives:
- Assess CVD risk factors in patients with T2DM and establish individualized treatment goals for comprehensive patient management
- Evaluate the therapeutic profiles of incretin-based therapies and the safe use of these agents, alone or in combination with other antihyperglycemic agents
- Identify patients that would benefit from insulin therapy and select insulin regimens that would best provide postprandial insulin replacement
Scott V. Joy, MD, CDE, FACP , Associate Professor of Medicine,
Duke University,
Durham, NC
Michael E. Cobble, MD , Private Practice,
Family Medicine,
Director,
Canyons Medical Center,
Sandy, UT
Jeffery S Freeman Philadelphia College of Osteopathic Medicine,
Philadelphia, PA
|
| 2:30 PM-2:45 PM |
PM Break
|
| 2:45 PM-4:00 PM |
Management of Diverticular Disease: New Strategies, New Approaches
Learning Objectives:
- Characterize the patterns of prevalence and risk factors for diverticular disease
- Integrate diagnostic approaches into the evaluation of patients with diverticular disease
- Formulate and apply appropriate medical management strategies when indicated for the treatment and prevention of diverticulitis
Sita Chokhavatia, MD Mount Sinai School of Medicine,
New York, NY
Martin H Floch, MD , MACG , AGAF , Clinical Professor of Medicine,
Digestive Disease Section,
Yale University School of Medicine,
New Haven, CT
|
|
pmiCME Updates Track 2 |
|
To date, the following organizations have provided educational grants in support of pmiCME Updates
Track 2: Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners, Daiichi Sankyo, Inc. and Eli Lilly USA, LLC., Forest Research Institute, a subsidiary of Forest Laboratories, Inc., and Ironwood Pharmaceuticals., Genzyme, a Sanofi company, Novo Nordisk Inc. and Vertex Pharmaceuticals Incorporated and Genentech.
|
| 7:00 AM-7:50 AM |
Registration & Breakfast
|
| 7:50 AM-8:00 AM |
Opening Remarks
|
| 8:00 AM-9:30 AM |
Insulin 101: An Introduction to Insulin Therapy in the 21st Century
Learning Objectives:
- Calculate appropriate insulin doses for initiating basal and basal-prandial insulin regimens in T2DM
- Demonstrate best practices in insulin injection and SMBG techniques to improve treatment adherence and potentially impact patient outcomes
- Apply pattern recognition to SMBG data to appropriately titrate insulin doses and adjust insulin regimens to specific patient needs
- Summarize the efficacy and safety findings from clinical trials of investigational insulins and the combination of incretin-based therapies with insulin
Javier Morales, MD , Vice President,
Principal Trials Investigator,
Advanced Internal Medicine Group, PC,
New Hyde Park, NY
Guillermo E Umpierrez, MD, FACP , FACE , Professor of Medicine,
Division of Endocrinology and Metabolism,
Section Chief, Diabetes and Endocrinology,
Director, Grady Health System,
Emory University School of Medicine,
Atlanta, GA
Debbie Hinnen, ARNP , BC-ADM , FAAN
|
| 9:30 AM-9:45 AM |
AM Break
|
| 9:45 AM-11:15 AM |
Getting Back on Track: Improving IBS Assessment and Management in Primary Care
Learning Objectives:
- Recognize the symptoms and accurately diagnose patients who have IBS
- Implement strategies to overcome barriers in diagnosing and treating patients with IBS
- Compare the safety and efficacy of currently available treatments when selecting therapy for patients with IBS
- Explain novel agents in development for the treatment of IBS and their potential implications for practice
Lawrence R. Schiller, MD, FACG
( Read Bio)
, Program Director,
Gastroenterology Fellowship,
Baylor University Medical Center,
Dallas, TX Lucinda A. Harris, MD, MS , Associate Professor of Medicine,
Mayo School of Medicine,
Scottsdale, AZ, , Consultant, Division Gastroenterology and Hepatology,
Department of Medicine,
Mayo Clinic Scottsdale,
Scottsdale, AZ
|
| 11:15 AM-12:30 PM |
What Primary Care Clinicians Need to Know about Managing Patients with Acute Coronary Syndrome
Learning Objectives:
- Confirm that patients with ACS are strictly adhering to ACEI/ARB, Aspirin, beta-blocker, statin, and thienopyridine therapy as recommended by the guidelines to reduce risk of reinfarction and mortality
- Recapitulate to patients with ACS, based on clinical trial evidence, the importance and potential side effects of dual antiplatelet therapy
Louis Kuritzky, MD
( Read Bio)
, Family Physician,
Clinical Assistant Professor,
Department of Community Health and Family Medicine,
University of Florida,
Gainesville, FL E. Magnus Ohman, MD, FACC, FRCPI , FESC , FSCAI , Professor of Medicine,
Associate Director, Duke Heart Center - Cardiology Clinics,
Director, Program for Advanced Coronary Disease,
Duke University Medical Center,
Durham, NC
|
| 12:30 PM-1:15 PM |
Lunch
|
| 1:15 PM-2:30 PM |
Targeting the Kidney in Managing the Patient with Type 2 Diabetes: A New Approach
Learning Objectives:
- Discuss the role of the kidney in glucose homeostasis
- Describe the contribution of the kidney to the sustained elevated glucose levels observed in individuals with uncontrolled type 2 diabetes.
- Explain the mechanism of action of therapies that act through the kidney to reduce hyperglycemia in type 2 diabetes
- Assess clinical efficacy and safety data, and identify the potential place of therapies that target the kidney in the management of type 2 diabetes
William T. Cefalu, MD , Douglas L. Manship Professorship in Diabetes,
Louisiana State University,
New Orleans, LA, , Professor, Chief,
Nutrition/Chronic Disease,
Pennington Biomedical Research Center,
Baton Rouge, LA
Vivian A Fonseca, MD , Professor of Medicine,
Section of Endocrinology,
Tulane University ,
New Orleans, LA
|
| 2:30 PM-2:45 PM |
PM Break
|
| 2:45 PM-4:00 PM |
Understanding the Impact of HCV and Therapeutic Considerations for the Front-Line Provider
Learning Objectives:
- Identify and screen patients at risk for HCV infection and counsel patients accordingly
- Illustrate knowledge gained on new triple-combination therapy combinations that include DAAs and collaborate with HCV specialist in the treatment of patients with chronic hepatitis C
- Monitor HCV patients on DAA therapy for potential adverse events, drug interactions, and issues relating to drug adherence
Nancy Reau, MD , Associate Professor of Medicine,
University of Chicago ,
Chicago, IL
Andrew Aronsohn, MD University of Chicago ,
Chicago, IL
|
| 4:00 PM-5:15 PM |
Defining the Role of Intra-articular Injections in the Management of Knee Osteoarthritis Pain
Learning Objectives:
- Explain the pathophysiology of OA of the knee and how current treatment options may affect various pain pathways and/or the potential for disease modification
- Consider individual patient and treatment characteristics (e.g., comorbidities, stage of disease, level of pain, drug tolerability, previous response to treatment) when initiating a multi-modal treatment plan for patients with knee OA
- Describe the individual clinical and patient characteristics that guide the selection of intraarticular corticosteroid and HA injection therapy
- Compare and contrast the clinical utility of intra-articular corticosteroids and/or HA injection therapy
Alfred Cianflocco, MD , Interim Director, Primary Care Sports Medicine,
Cleveland Clinic Sports Health,
Department of Orthopaedic Surgery,
Orthopaedic and Rheumatologic Institute,
Cleveland Clinic,
Cleveland, OH
|
